Nasdaq Panel Grants KALA BIO Continued Listing With $1.00 Bid Cure Deadlines
KALA sits 31% above its 52-week low of $3.438.
Summary
Nasdaq's Hearings Panel allowed KALA BIO to stay listed, conditioned on a $1.00 closing bid for ten consecutive business days by November 30, 2026 and daily compliance through February 23, 2027. Failure reopens delisting risk.
Key Events · Legal and Risk Events · KALA
-
Panel Grants Conditional Continued Listing
On November 13, 2026 the Nasdaq Hearings Panel granted KALA BIO's request to remain on the Nasdaq Capital Market, subject to bid-price conditions, after the company met with the Panel on October 6, 2026.
-
Ten-Day $1.00 Bid Deadline
The company must evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026.
-
Compliance Through February 2027
KALA must hold a $1.00 closing bid every trading day after November 30, 2026 until February 23, 2027; maintaining compliance triggers a one-year discretionary monitor.
-
Seven-Day Cure Window on New Deficiencies
If the company breaches any other Nasdaq listing rule before February 23, 2027, it gets seven days to advise the Panel on a cure plan, and the Panel decides whether to grant an exception or delist.
Analysis · KALA · Life Sciences
KALA BIO keeps its Nasdaq listing, but only on a clock. The Hearings Panel requires a closing bid of at least $1.00 for ten straight business days by November 30, 2026, then a $1.00 close every trading day through February 23, 2027. The 1-for-30 reverse split that took effect November 13, 2026 was the mechanical fix; whether the stock actually holds above $1.00 is the open question. Missing the November 30 deadline or tripping any other listing rule before February 23, 2027 puts delisting back on the table, with only seven days to present a cure plan. The company states there can be no assurance it will meet the conditions.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KALA was trading at $4.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $3.44 to $2,865.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.